34271-50-6

Basic information

• Product Name: S-(+)-Albuterol
• Synonyms: (S)-(+)-Salbutamol;(S)-Albuterol;(S)-Salbutamol;1,3-Benzenedimethanol, a1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-, (a1S)- (9CI);1,3-Benzenedimethanol, a1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-, (S)-;m-Xylene-a,a'-diol, a1-[(tert-butylamino)methyl]-4-hydroxy-, (S)-(+)- (8CI);S-(+)-Albuterol
• CAS NO: 34271-50-6
• Molecular Formula: C13H21 N O3
• Molecular Weight: 239.31
• Mol File: 34271-50-6.mol
• Article Data: 29

Chemical Properties

• Boiling Point: 433.5°Cat760mmHg
• Flash Point: 159.5°C
• Appearance: /
• Density: 1.152g/cm³
• Vapor Pressure: 2.78E-08mmHg at 25°C
• Refractive Index: 1.566
• PKA: 9.99±0.31(Predicted)
• CAS DataBase Reference: S-(+)-Albuterol(CAS DataBase Reference)
• NIST Chemistry Reference: S-(+)-Albuterol(34271-50-6)
• EPA Substance Registry System: S-(+)-Albuterol(34271-50-6)

Safety Data

• Hazardous Substances Data: 34271-50-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3/t12-/m1/s1

Upstream product

• 115787-52-5 5-(2-tert-Butylamino-acetyl)-2-hydroxy-benzaldehyde 
• 24085-03-8 α-[(benzyl-tert-butylamino)methyl]-m-xylene-4,α,α'-triol 
• 324000-05-7 2-tert-butylamino-1-(4-hydroxy-2-hydroxymethyl-phenyl)ethanol 
• 18559-94-9 Salbutamol 
• 115787-50-3 5-(2-bromoacetyl)-2-hydroxybenzaldehyde 
• 90-02-8 salicylaldehyde 
• 115787-53-6 5-<<(1,1-Dimethylethyl)amino>acetyl>-2-hydroxybenzaldehyde hydrochloride 
• 24085-06-1 4'-acetoxy-3'-(acetoxymethyl)acetophenone 
• 99-93-4 4-Hydroxyacetophenone 
• 75-64-9 tert-butylamine 
• 238762-31-7 (R)-2-(N-tert-butylamino)-1-(2,2-dimethyl-4H-benzo[3,4-e]1,3-dioxin-6-yl)ethanol 
• 69-72-7 salicylic acid 

Downstream Products

• 54208-72-9 2-(tert-butylamino)-1-(2,2-dimethyl-4H-benzo[d][1,3]dioxan-6-yl)ethanol 
• 324000-05-7 2-tert-butylamino-1-(4-hydroxy-2-hydroxymethyl-phenyl)ethanol 
• 102015-18-9 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-nitrophenol 
• 62084-23-5 (+/-)-albuterol tri(trimethylsilyl)ether 
• 35459-13-3 (-)-(R)-salbutamol acetate 

Relevant articles and documents

Effect of additives on eremomycin sorbent selectivity in separation of salbutamol enantiomers using supercritical fluid chromatography

A regime is found in which chiral stationary phase based on macrocyclic glycopeptide eremomycin allows separation of salbutamol sulfate enantiomers in supercritical fluid chromatography. Enantioseparation occurs only when two dynamic modifiers are used simultaneously: isopropylamin + trifluoroacetic acid or isopropylamin + ammonium acetate. Amine molar concentration in mobile phase has to be higher than acid molar concentration, otherwise enantiomers coelute. We suppose that with amine excess a mechanism of enantiorecognition is realized which involves ionic sorbent-sorbate interactions. Such mechanism is well-known for glycopeptide chiral selectors in liquid chromatography, but for supercritical fluid chromatography it is reported for the first time.

Preparation method of racemic salbutamol

The invention discloses a preparation method of racemic salbutamol. The method comprises the following steps: taking 5-bromosalicylaldehyde as a raw material, carrying out reduction reaction on the 5-bromosalicylaldehyde and sodium borohydride to obtain an intermediate I; carrying out alkylation reaction on the intermediate I, sodium hydride and benzyl halide to obtain an intermediate II; carryingout cross-coupling reaction on the intermediate II and vinyl potassium trifluoroborate to obtain an intermediate III; carrying out addition reaction on the intermediate III and N-bromo succinimide toobtain an intermediate IV; carrying out alkylation reaction on the intermediate IV and tert-butylamine to obtain an intermediate V; and carrying out deprotection reaction on the intermediate V in a hydrogen atmosphere to obtain the racemic salbutamol. The 5-bromosalicylaldehyde is used as a reaction raw material for the first time to reduce the production cost, and bromine atoms are introduced, so that functional groups can be directionally introduced to the 5th site by the reaction, and the selectivity and yield of the reaction are improved; no high-risk highly toxic reagent is involved; andthe Suzuki-Miyaura cross-coupling reaction is applied to synthesis of salbutamol for the first time, and a catalytic amount of palladium catalyst is used, so that efficient introduction of double bonds on an aromatic ring can be realized, and the cost is reduced while the reaction yield is increased.

Preparation and characterization of a new open-tubular capillary column for enantioseparation by capillary electrochromatography

In order to use the enantioseparation capability of cationic cyclodextrin and to combine the advantages of capillary electrochromatography (CEC) with open-tubular (OT) column, in this study, a new OT-CEC, coated with cationic cyclodextrin (1-allylimidazolium-β-cyclodextrin [AI-β-CD]) as chiral stationary phase (CSP), was prepared and applied for enantioseparation. Synthesized AI-β-CD was characterized by infrared (IR) spectrometry and mass spectrometry (MS). The preparation conditions for the AI-β-CD-coated column were optimized with the orthogonal experiment design L9(34). The column prepared was characterized by scanning electron microscopy (SEM) and elemental analysis (EA). The results showed that the thickness of stationary phase in the inner surface of the AI-β-CD-coated columns was about 0.2 to 0.5?μm. The AI-β-CD content in stationary phase based on the EA was approximately 2.77?mmol·m?2. The AI-β-CD-coated columns could separate all 14 chiral compounds (histidine, lysine, arginine, glutamate, aspartic acid, cysteine, serine, valine, isoleucine, phenylalanine, salbutamol, atenolol, ibuprofen, and napropamide) successfully in the study and exhibit excellent reproducibility and stability. We propose that the column, coated with AI-β-CD, has a great potential for enantioseparation in OT-CEC.